HIF-2α inhibitor belzutifan to be fast-tracked for approval for VHL kidney cancer

Kidney cancers frequently have mutations in a gene called the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in a number of changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks […]

read more

Avelumab plus axitinib combination available via EAMS

It has just been announced that the avelumab plus axitinib combination has received positive scientific opinion for the Early Access to Medicines Scheme (EAMS) for the first-line treatment of advanced renal cell carcinoma (RCC). EAMS aims to give patients with life-threatening or seriously debilitating conditions access to medicines that do not yet have a marketing […]

read more
Showing all 2 results